심방세동 환자의 고주파 도자절제술 전·후의 항응고약물요법 사용실태 분석
Evaluation of Peri-procedural Anticoagulation Drug Therapy undergoing Radiofrequency Ablation in Patients with Atrial Fibrillation
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Radiofrequency ablation (RA) is being used to manage atrial fibrillation (AF) with patients failed at the 1st-line anti-arrhythmic medications. Patients undergoing this procedure are at increased risk of thromboembolism after ablation, and anticoagulation management surrounding the ablation remains controversial. Although no conclusive recommendations can be made,published guidelines and data support therapeutic anticoagulation with warfarin. The purpose of this study was to analyze effectiveness of current therapy and to find factors fluctuate International Normalized Ratio (INR) values in patients undergone RA followed by anticoagulation service (ACS). Retrospective review was conducted utilizing database in a hospital. Among 110 patients under warfarin around ablation between January 2006 to September 2007, 54 patients were selected and allocated into 2 groups: Group A included 47 who discontinued warfarin after ablation, while 7 in B continued the medication. Information on demographics, amount and length of warfarin dosing, INR values and measuring frequencies, and the causing factors on INR fluctuation were abstracted. Differences were analyzed using chi-squared test, Fisher's Exact test, and unpaired Student t-test. Mean amount of warfarin before and after surgery was 4.0 mg, 4.1 mg in Group A and was 5.1 mg,4.6 mg in Group B, respectively. Average duration of warfarin doing before ablation was 73.7 days in Group A, 129.9 days in B with no significant difference (p = 0.312). The duration time of warfarin on groups after ablation lasted several months. The number of checking INRs was 4.1 and 7.6, respectively. Inter-individual variability of INR fluctuations were 2.1 ± 0.6 in Group A and 2.2 ± 0.7 in B which were not significantly different (p = 0.062). 164 cases of decreased INR were: ‘omission in taking medication, stressfulness and headache, ‘increased intake of high vitamin K foods’, ‘lifestyle change of increased physical activities’, and ‘increase of food-intakes’. To the contrary, 36 cases of increased INR were: ‘reduce of food-intake’, ‘use of non-prescription drugs’, ‘reduction in physical activities’, and ‘excessive restriction on food-intake’, consecutively. In conclusion,the study validated therapeutic outcomes of RA patients who we treated with standard guideline and demonstrated 9 factors of INR fluctuations in the patient. A well-trained, pharmacist-monitored anticoagulation service could reduce the risk of adverse effects and prevent complications in patients with AF around RA operation
Abstract
Radiofrequency ablation (RA) is being used to manage atrial fibrillation (AF) with patients failed at the 1st-line anti-arrhythmic medications. Patients undergoing this procedure are at increased risk of thromboembolism after ablation, and anticoagulation management surrounding the ablation remains controversial. Although no conclusive recommendations can be made,published guidelines and data support therapeutic anticoagulation with warfarin. The purpose of this study was to analyze effectiveness of current therapy and to find factors fluctuate International Normalized Ratio (INR) values in patients undergone RA followed by anticoagulation service (ACS). Retrospective review was conducted utilizing database in a hospital. Among 110 patients under warfarin around ablation between January 2006 to September 2007, 54 patients were selected and allocated into 2 groups: Group A included 47 who discontinued warfarin after ablation, while 7 in B continued the medication. Information on demographics, amount and length of warfarin dosing, INR values and measuring frequencies, and the causing factors on INR fluctuation were abstracted. Differences were analyzed using chi-squared test, Fisher's Exact test, and unpaired Student t-test. Mean amount of warfarin before and after surgery was 4.0 mg, 4.1 mg in Group A and was 5.1 mg,4.6 mg in Group B, respectively. Average duration of warfarin doing before ablation was 73.7 days in Group A, 129.9 days in B with no significant difference (p = 0.312). The duration time of warfarin on groups after ablation lasted several months. The number of checking INRs was 4.1 and 7.6, respectively. Inter-individual variability of INR fluctuations were 2.1 ± 0.6 in Group A and 2.2 ± 0.7 in B which were not significantly different (p = 0.062). 164 cases of decreased INR were: ‘omission in taking medication, stressfulness and headache, ‘increased intake of high vitamin K foods’, ‘lifestyle change of increased physical activities’, and ‘increase of food-intakes’. To the contrary, 36 cases of increased INR were: ‘reduce of food-intake’, ‘use of non-prescription drugs’, ‘reduction in physical activities’, and ‘excessive restriction on food-intake’, consecutively. In conclusion,the study validated therapeutic outcomes of RA patients who we treated with standard guideline and demonstrated 9 factors of INR fluctuations in the patient. A well-trained, pharmacist-monitored anticoagulation service could reduce the risk of adverse effects and prevent complications in patients with AF around RA operation
참고문헌 (36)
- Benjamin EJ, "Impact of atrial fibrillation on the risk of death", Circulation, 98, pp.946~952 (1998)
- Feinburg WM, "Prevalence, age distribution, a gender of patients with atrial fibrillation: analysis and implications", Arch Intern Med, 155, pp.469~473 (1995)
- Ryder KM, "Epidemiology and significance of atrial fibrillation", Am J Cardiol, 84, pp.131R~138R (1999)
- "AHA 2006 Guidelines for the Management of Patients with Atrial Fibrillation", 2006 American Heart Association, Inc., e257~e354 (2006)
- Pratola C, "Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm?", Circulation, 117, pp.136~143 (2008)
- Mateos JC, "Radiofrequency catheter ablation of atrial fibrillation guided by spectral mapping of atrial fibrillation nests in sinus rhythm", Arq Bras Cardiol, 89, pp.124~134 (2007)
- Martìn-Suàrez S, "Surgery for atrial fibrillation with radiofrequency ablation", Interact Cardiovasc Thorac Surg, 6, pp.71~76 (2007)
- Nehra D, "Complete pulmonary venous occlusion after radiofrequency ablation for atrial fibrillation", Ann Thorac Surg, 87, pp.292~295 (2009)
- De Piccoli B, "Role of transoesophageal echocardiography in evaluating the effect of catheter ablation of atrial fibrillation on anatomy and function of the pulmonary veins", Europace, 10, pp.1079~1084 (2008)
- Scanavacca MI, "Pulmonary vein stenosis complicating catheter ablation of focal atrial fibrillation", J Cardiovasc Electrophysiol, 11, pp.677~681 (2000)
- "American College of Cardiology", American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation), 2001
- Bubien RS, "Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias", Circulation, 94, pp.1585~1591 (1996)
- Hindricks G, "Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence", Circulation, 112, pp.307~313 (2005)
- Isma'eel H, "Anticoagulation clinics are needed in developing countries", Int J Cardiol, 115, pp.410~411 (2007)
- Burkiewicz JS, "Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation", Pharmacotherapy, 25, pp.1062~1067 (2005)
- Matchar DB, "Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial", Am J Med, 113, pp.42~51 (2002)
- Mortada ME, "Periprocedural anticoagulation for atrial fibrillation ablation", J Cardiovasc Electrophysiol, 19, pp.362~366 (2008)
- Oral H, "Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation", Circulation, 114, pp.759~765 (2006)
- European Heart Rhythm Association, "ACC", AHA, American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation), pp.J Am Coll Cardiol, 2006[DOI]
- Laupacis A, "Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials", Arch Intern Med, 154, pp.1449~1457 (1994)
- Vazquez SR, "Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation", Thrombosis Research, 126, pp.69~77 (2010)
- Jones C, "Enhancing patient care via a pharmacistmanaged rural anticoagulation clinic", Healthc Q, 13, pp.69~74 (2009)
- Bond CA, "Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions", Pharmacotherapy, 24, pp.953~963 (2004)
- Garcia DA, "Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum", Ann Pharmacother, 42, pp.979~988 (2008)
- Poon IO, "The impact of pharmacist-managed oral anticoagulation therapy in older veterans", J Clin Pharm Ther, 32, pp.21~29 (2007)
- Sullivan PW, "The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US", Pharmacoeconomics, 24, pp.1021~1033 (2006)
- Dager WE, "Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service", Ann Pharmacother, 34, pp.567~572 (2000)
- Waterman AD, "Establishing and running an effective telephone-based anticoagulation service", J Vasc Nurs, 19, pp.126~134 (2001)
- Waterman AD, "Patient and Physician Satisfaction with a Telephone-based Anticoagulation Service", J Gen Intern Med, 16, pp.460~463 (2001)
- Chenella FC, "Comparison of physician and pharmacist management of anticoagulant therapy of inpatients", Am J Hosp Pharm, 40, pp.1642~1645 (1983)
- Tschol N, "Comparison of physician- and pharmacist-managed warfarin sodium treatment in open heart surgery patients", Can J Cardiol, 19, pp.1413~1417 (2003)
- Chiquette E, "Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs", Arch Intern Med, 158, pp.1641~1647 (1998)
- Gray DR, "Costjustification of a clinical pharmacist-managed anticoagulation clinic", Drug Intell Clin Pharm, 19, pp.575~580 (1985)
- Anderson RJ, "Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service", J Manag Care Pharm, 10, pp.159~165 (2004)
- Lip GY, "Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and", or undergoing percutaneous coronary intervention, Thromb Haemost, pp.2010, 103[DOI]
- Ross KA, "Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements", J Human Genet (advance online publication 17 June 2010); doi: 10.1038, 2010